LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital has reaffirmed a Buy rating on Sionna Therapeutics, Inc. (SION) with a price target of $60.00. Analyst Gaurav Maini has an average return of 12.2% and a 75% success rate. Sionna also received a Buy rating from TD Cowen, while RBC Capital maintained a Sell rating.
In a report released today, Gaurav Maini from LifeSci Capital maintained a Buy rating on Sionna Therapeutics, Inc., with a price target of $60.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Maini covers the Healthcare sector, focusing on stocks such as Sionna Therapeutics, Inc., Tenax Therapeutics, and Tectonic Therapeutic. According to TipRanks, Maini has an average return of 12.2% and a 75.00% success rate on recommended stocks.
In addition to LifeSci Capital, Sionna Therapeutics, Inc. also received a Buy from TD Cowen’s Ritu Baral in a report issued on May 13. However, on May 12, RBC Capital maintained a Sell rating on Sionna Therapeutics, Inc. (NASDAQ: SION).